

# Joseph L Witztum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4883027/publications.pdf>

Version: 2024-02-01

328  
papers

53,814  
citations

807

118  
h-index

1341

223  
g-index

342  
all docs

342  
docs citations

342  
times ranked

36521  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. <i>European Heart Journal</i> , 2022, 43, 1401-1412.	1.0	78
2	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1035-1046.	1.2	65
3	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. <i>Atherosclerosis</i> , 2022, 346, 68-74.	0.4	7
4	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. <i>Journal of Lipid Research</i> , 2021, 62, 100053.	2.0	62
5	Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. <i>Atherosclerosis</i> , 2021, 324, 102-108.	0.4	19
6	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
7	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. <i>Immunity</i> , 2021, 54, 1561-1577.e7.	6.6	260
8	Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. <i>Aging Cell</i> , 2021, 20, e13442.	3.0	17
9	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. <i>Circulation</i> , 2021, 144, 1940-1954.	1.6	33
10	Statins and increases in Lp(a): an inconvenient truth that needs attention. <i>European Heart Journal</i> , 2020, 41, 192-193.	1.0	20
11	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020, 41, 2275-2284.	1.0	265
12	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, 244-255.	13.9	559
13	Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 189-206.e8.	7.2	113
14	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). <i>Journal of Lipid Research</i> , 2020, 61, 1263-1270.	2.0	8
15	CD1d Selectively Down Regulates the Expression of the Oxidized Phospholipid-Specific E06 IgM Natural Antibody in Ldlr <sup>-/-</sup> Mice. <i>Antibodies</i> , 2020, 9, 30.	1.2	3
16	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
17	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359.	2.0	96
18	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. <i>Heart</i> , 2020, 106, 738-745.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. <i>Nucleic Acid Therapeutics</i> , 2020, 30, 94-103.	2.0	22
20	An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. <i>Science</i> , 2020, 367, 652-660.	6.0	183
21	Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. <i>Immunity</i> , 2020, 52, 1057-1074.e7.	6.6	248
22	A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 170-185.	3.1	10
23	Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. <i>Cardiovascular Research</i> , 2019, 115, 179-189.	1.8	61
24	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542.	13.9	359
25	Apolipoprotein Profiles in Very Preterm and Term-Born Preschool Children. <i>Journal of the American Heart Association</i> , 2019, 8, e011199.	1.6	6
26	N-acetyl galactosamine-conjugated antisense drug to <i>APOC3</i> mRNA, triglycerides and atherogenic lipoprotein levels. <i>European Heart Journal</i> , 2019, 40, 2785-2796.	1.0	159
27	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. <i>Journal of Lipid Research</i> , 2019, 60, 2082-2089.	2.0	35
28	Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked to Human Coronary Atherosclerosis. <i>Circulation Research</i> , 2019, 125, e55-e70.	2.0	42
29	ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. <i>Journal of Lipid Research</i> , 2019, 60, 1379-1395.	2.0	48
30	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2150-2162.	1.2	187
31	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. <i>CJC Open</i> , 2019, 1, 131-140.	0.7	38
32	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. <i>Journal of the Endocrine Society</i> , 2019, 3, 2397-2410.	0.1	32
33	A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. <i>Journal of Lipid Research</i> , 2019, 60, 436-445.	2.0	7
34	CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice. <i>Molecular Metabolism</i> , 2019, 20, 89-101.	3.0	21
35	Relationship between $\Delta\text{LDL-C}$ , estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. <i>Journal of Clinical Lipidology</i> , 2018, 12, 702-710.	0.6	53
36	RNA-Targeted Therapeutics. <i>Cell Metabolism</i> , 2018, 27, 714-739.	7.2	556

#	ARTICLE	IF	CITATIONS
37	Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. <i>Journal of Immunology</i> , 2018, 200, 1702-1717.	0.4	36
38	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 321-335.	1.2	39
39	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 338-347.	0.6	18
40	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
41	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 122-129.e2.	0.6	36
42	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1493-1501.e11.	0.6	7
43	The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 898-907.e2.	0.6	44
44	Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS. <i>Journal of Clinical Lipidology</i> , 2018, 12, 537.	0.6	13
45	Examining the High Disease Burden and Impact on Quality of Life in Familial Chylomicronemia Syndrome. <i>Journal of Clinical Lipidology</i> , 2018, 12, 536-537.	0.6	0
46	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1313-1323.	0.6	66
47	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. <i>Nature</i> , 2018, 558, 301-306.	13.7	359
48	Oxidation-specific epitopes restrain bone formation. <i>Nature Communications</i> , 2018, 9, 2193.	5.8	41
49	Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. <i>Journal of the American College of Cardiology</i> , 2017, 69, 147-158.	1.2	46
50	The Effects of 2'-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials. <i>Nucleic Acid Therapeutics</i> , 2017, 27, 121-129.	2.0	101
51	Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 524-533.	5.5	165
52	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1206-1212.	1.1	56
53	Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1213-1221.	1.1	50
54	Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. <i>New England Journal of Medicine</i> , 2017, 377, 222-232.	13.9	482

#	ARTICLE	IF	CITATIONS
55	Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1570-1578.	1.1	60
56	RELATIONSHIP OF BIOMARKERS OF OXIDIZED LIPOPROTEINS TO ETHNICITY, SUBCLINICAL ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS OVER A 10.5 YEAR FOLLOW-UP IN THE DALLAS HEART STUDY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 64.	1.2	0
57	PRO-INFLAMMATORY INTERLEUKIN-1 GENOTYPES AFFECT THE ASSOCIATION OF C-REACTIVE PROTEIN FOR ANGIOGRAPHICALLY DETERMINED CORONARY ARTERY DISEASE AND CARDIOVASCULAR EVENTS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 193.	1.2	1
58	The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 415-423.	0.6	44
59	Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. <i>Atherosclerosis</i> , 2017, 260, 1-7.	0.4	6
60	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). <i>Atherosclerosis</i> , 2017, 263, e10.	0.4	23
61	Adenoviral intramyocardial VEGF-D <sup>17</sup> N <sup>17</sup> C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. <i>European Heart Journal</i> , 2017, 38, 2547-2555.	1.0	109
62	Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2017, 2, 229-240.	1.9	61
63	Interim Results of the Investigation of Findings and Observations Captured in Burden of Illness Survey in FCS Patients (IN-FOCUS): US Respondents. <i>Journal of Clinical Lipidology</i> , 2017, 11, 804-805.	0.6	0
64	Characterizing Familial Chylomicronemia Syndrome: Baseline data of the APPROACH Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 816.	0.6	1
65	Plasma Proteomics for Epidemiology. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	17
66	<i>LPA</i> Gene, Ethnicity, and Cardiovascular Events. <i>Circulation</i> , 2017, 135, 251-263.	1.6	83
67	Cholesterol Accumulation in CD11c+ Immune Cells Is a Causal and Targetable Factor in Autoimmune Disease. <i>Immunity</i> , 2016, 45, 1311-1326.	6.6	99
68	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2016, 10, 594-603.	0.6	88
69	Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. <i>Journal of Clinical Lipidology</i> , 2016, 10, 680-681.	0.6	25
70	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1011-1021.	0.6	104
71	Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 682-691.	1.1	69
72	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624.	1.6	396

#	ARTICLE	IF	CITATIONS
73	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. <i>Lancet, The</i> , 2016, 388, 2239-2253.	6.3	584
74	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. <i>Journal of Lipid Research</i> , 2016, 57, 697-705.	2.0	24
75	Innate sensing of oxidation-specific epitopes in health and disease. <i>Nature Reviews Immunology</i> , 2016, 16, 485-497.	10.6	271
76	Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. <i>Cell Reports</i> , 2016, 14, 2348-2361.	2.9	66
77	Lipoprotein (a): Coming of Age at Last. <i>Journal of Lipid Research</i> , 2016, 57, 336-339.	2.0	21
78	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. <i>Journal of Lipid Research</i> , 2016, 57, 706-713.	2.0	83
79	Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptorâ€“Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 456-465.	1.1	53
80	ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. <i>Journal of Clinical Investigation</i> , 2016, 126, 2855-2866.	3.9	186
81	CEP Is an Important and Ubiquitous Oxidation Specific Epitope Recognized by Innate Pattern Recognition Receptors. <i>Circulation Research</i> , 2015, 117, 305-308.	2.0	1
82	â€“LDL-Câ€“=â€“LDL-C+â€“Lp(a)-C. <i>Current Opinion in Lipidology</i> , 2015, 26, 169-178.	1.2	122
83	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 689-699.	1.1	165
84	Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 989-98.	1.2	54
85	Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 229-236.	1.1	49
86	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2015, 373, 438-447.	13.9	445
87	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. <i>Lancet, The</i> , 2015, 386, 1472-1483.	6.3	386
88	Re-Evaluation of the Anticoagulant Properties of High-Density Lipoproteinâ€“Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 570-572.	1.1	11
89	B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. <i>Circulation Research</i> , 2015, 117, e28-39.	2.0	111
90	SYK regulates macrophage MHC-II expression via activation of autophagy in response to oxidized LDL. <i>Autophagy</i> , 2015, 11, 785-795.	4.3	77

#	ARTICLE	IF	CITATIONS
91	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1286-1295.	1.2	61
92	Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. <i>Journal of Lipid Research</i> , 2015, 56, 722-736.	2.0	264
93	Heritability of Biomarkers of Oxidized Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1704-1711.	1.1	44
94	Daniel Steinberg, 1922–2015. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9791-9792.	3.3	1
95	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1236-1246.	1.2	295
96	Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. <i>Journal of Lipid Research</i> , 2015, 56, 440-448.	2.0	96
97	Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). <i>Transactions of the American Ophthalmological Society</i> , 2015, 113, T5.	1.4	9
98	Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
99	Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e112483.	1.1	174
100	Targeting APOC3 in the Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 2200-2206.	13.9	376
101	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 719-736.	1.1	18
102	Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1961-1971.	1.2	88
103	New Therapeutic Targets for Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 478-480.	1.2	38
104	The Influence of Innate and Adaptive Immune Responses on Atherosclerosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 73-102.	9.6	227
105	Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive Immunity. <i>Circulation</i> , 2014, 129, 1677-1687.	1.6	107
106	Reducing Macrophage Proteoglycan Sulfation Increases Atherosclerosis and Obesity through Enhanced Type I Interferon Signaling. <i>Cell Metabolism</i> , 2014, 20, 813-826.	7.2	65
107	ABCG1 Is Required for Pulmonary B-1 B Cell and Natural Antibody Homeostasis. <i>Journal of Immunology</i> , 2014, 193, 5637-5648.	0.4	28
108	Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. <i>Journal of Lipid Research</i> , 2014, 55, 2137-2155.	2.0	47

#	ARTICLE	IF	CITATIONS
109	Interleukin-3/Granulocyte Macrophage Colony-Stimulating Factor Receptor Promotes Stem Cell Expansion, Monocytosis, and Atheroma Macrophage Burden in Mice With Hematopoietic ApoE Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 976-984.	1.1	65
110	Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2014, 64, 851-860.	1.2	231
111	B Cells and Humoral Immunity in Atherosclerosis. <i>Circulation Research</i> , 2014, 114, 1743-1756.	2.0	241
112	Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2014, 63, 1724-1734.	1.2	110
113	Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B Cell Proliferation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2771-2779.	1.1	46
114	Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. <i>Current Opinion in Pharmacology</i> , 2013, 13, 168-179.	1.7	74
115	MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. <i>Journal of Lipid Research</i> , 2013, 54, 1877-1883.	2.0	76
116	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. <i>Atherosclerosis</i> , 2013, 226, 161-164.	0.4	41
117	Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2169-2179.	1.2	71
118	Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100. <i>Frontiers in Immunology</i> , 2013, 4, 493.	2.2	78
119	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). <i>Journal of Lipid Research</i> , 2013, 54, 2815-2830.	2.0	174
120	Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. <i>Annals of Neurology</i> , 2013, 73, 129-135.	2.8	96
121	Development and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors. <i>Journal of Lipid Research</i> , 2013, 54, 3206-3214.	2.0	9
122	Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages. <i>PLoS ONE</i> , 2013, 8, e83145.	1.1	44
123	Adaptive immunity in atherogenesis: new insights and therapeutic approaches. <i>Journal of Clinical Investigation</i> , 2013, 123, 27-36.	3.9	163
124	IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde-Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope. <i>PLoS ONE</i> , 2013, 8, e65203.	1.1	13
125	Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. <i>Journal of Lipid Research</i> , 2012, 53, 1316-1326.	2.0	44
126	Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. <i>Journal of Lipid Research</i> , 2012, 53, 2773-2790.	2.0	131



#	ARTICLE	IF	CITATIONS
127	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2012, 53, 1670-1678.	2.0	53
128	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 3066-3075.	1.1	27
129	B-Cell Aortic Homing and Atheroprotection Depend on Id3. <i>Circulation Research</i> , 2012, 110, e1-12.	2.0	102
130	Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2218-2229.	1.2	187
131	The Bcl6-SMRT/NCOR Cistrome Represses Inflammation to Attenuate Atherosclerosis. <i>Cell Metabolism</i> , 2012, 15, 554-562.	7.2	111
132	In Vivo Detection of Oxidation-Specific Epitopes in Atherosclerotic Lesions Using Biocompatible Manganese Molecular Magnetic Imaging Probes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 616-626.	1.2	55
133	Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1426-1437.	1.2	64
134	Increased Expression of Oxidation-Specific Epitopes and Apoptosis Are Associated With Haptoglobin Genotype. <i>Journal of the American College of Cardiology</i> , 2012, 60, 112-119.	1.2	36
135	Oxidized phospholipids impair pulmonary antibacterial defenses: Evidence in mice exposed to cigarette smoke. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 253-259.	1.0	44
136	Design and Synthesis of a Stable Oxidized Phospholipid Mimic with Specific Binding Recognition for Macrophage Scavenger Receptors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 8178-8182.	2.9	6
137	Antisense oligonucleotides for the treatment of dyslipidaemia. <i>European Heart Journal</i> , 2012, 33, 1451-1458.	1.0	91
138	Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. <i>Nature</i> , 2011, 478, 76-81.	13.7	469
139	Oxidative damage in multiple sclerosis lesions. <i>Brain</i> , 2011, 134, 1914-1924.	3.7	585
140	Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1611-1621.	1.2	113
141	Mycophenolate Mofetil Decreases Atherosclerotic Lesion Size by Depression of Aortic T-Lymphocyte and Interleukin-17-Mediated Macrophage Accumulation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2194-2204.	1.2	35
142	Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1715-1727.	1.2	100
143	4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. <i>FASEB Journal</i> , 2011, 25, 290-300.	0.2	44
144	Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. <i>Circulation Research</i> , 2011, 108, 235-248.	2.0	527

#	ARTICLE	IF	CITATIONS
145	The inhibitory Fc $\gamma$ RIIb modulates the inflammatory response and influences atherosclerosis in male apoE $\alpha^{-/-}$ mice. <i>Atherosclerosis</i> , 2011, 214, 73-80.	0.4	46
146	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1619-1624.	0.5	128
147	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. <i>Journal of Lipid Research</i> , 2011, 52, 1829-1836.	2.0	113
148	Is Atherosclerosis an Allergic Disease?. <i>Circulation Research</i> , 2011, 109, 1103-1104.	2.0	10
149	Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. <i>Biomarkers in Medicine</i> , 2011, 5, 673-694.	0.6	156
150	Research Resource: Comparative Nuclear Receptor Atlas: Basal and Activated Peritoneal B-1 and B-2 Cells. <i>Molecular Endocrinology</i> , 2011, 25, 529-545.	3.7	12
151	In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. <i>Journal of Clinical Investigation</i> , 2011, 121, 4861-4869.	3.9	81
152	Deletion of the Basement Membrane Heparan Sulfate Proteoglycan Type XVIII Collagen Causes Hypertriglyceridemia in Mice and Humans. <i>PLoS ONE</i> , 2010, 5, e13919.	1.1	46
153	Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. <i>Journal of Lipid Research</i> , 2010, 51, 3324-3330.	2.0	67
154	Low Doses of Lipopolysaccharide and Minimally Oxidized Low-Density Lipoprotein Cooperatively Activate Macrophages via Nuclear Factor $\kappa$ B and Activator Protein-1. <i>Circulation Research</i> , 2010, 107, 56-65.	2.0	162
155	Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. <i>Cardiovascular Research</i> , 2010, 85, 224-231.	1.8	45
156	ABCA1 and ABCG1 Protect Against Oxidative Stress-Induced Macrophage Apoptosis During Efferocytosis. <i>Circulation Research</i> , 2010, 106, 1861-1869.	2.0	160
157	Oxidized Low-Density Lipoprotein and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2311-2316.	1.1	371
158	Modifying Apolipoprotein A-I by Malondialdehyde, but Not by an Array of Other Reactive Carbonyls, Blocks Cholesterol Efflux by the ABCA1 Pathway. <i>Journal of Biological Chemistry</i> , 2010, 285, 18473-18484.	1.6	124
159	Oxidized Cholesteryl Esters and Phospholipids in Zebrafish Larvae Fed a High Cholesterol Diet. <i>Journal of Biological Chemistry</i> , 2010, 285, 32343-32351.	1.6	80
160	Deficiency of Antigen-Presenting Cell Invariant Chain Reduces Atherosclerosis in Mice. <i>Circulation</i> , 2010, 122, 808-820.	1.6	76
161	When Monocytes Come (Too) Close to Our Hearts. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1639-1641.	1.2	7
162	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. <i>Journal of the American College of Cardiology</i> , 2010, 56, 946-955.	1.2	139

#	ARTICLE	IF	CITATIONS
163	Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress. <i>Cell Metabolism</i> , 2010, 12, 467-482.	7.2	397
164	The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. <i>Atherosclerosis</i> , 2010, 209, 498-503.	0.4	36
165	Effects of low-fat, high-carbohydrate diet on plasma lipoprotein(a) and oxidized phospholipids. <i>FASEB Journal</i> , 2010, 24, 1b365.	0.2	0
166	Response to Letter Regarding Article, "Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia". <i>Circulation</i> , 2009, 119, .	1.6	0
167	Phosphoinositide 3-Kinase p110 $\beta$ Regulates Natural Antibody Production, Marginal Zone and B-1 B Cell Function, and Autoantibody Responses. <i>Journal of Immunology</i> , 2009, 183, 5673-5684.	0.4	122
168	Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 3236-45.	3.9	176
169	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. <i>Circulation</i> , 2009, 119, 1711-1719.	1.6	117
170	Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein. <i>Circulation Research</i> , 2009, 104, 210-218.	2.0	364
171	Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9546-9547.	3.3	90
172	Macrophage Apoptosis Exerts Divergent Effects on Atherogenesis as a Function of Lesion Stage. <i>Circulation</i> , 2009, 119, 1795-1804.	1.6	194
173	Critical Role of IL-17RA in Immunopathology of Influenza Infection. <i>Journal of Immunology</i> , 2009, 183, 5301-5310.	0.4	315
174	Lipoprotein Accumulation in Macrophages via Toll-Like Receptor-4-Dependent Fluid Phase Uptake. <i>Circulation Research</i> , 2009, 104, 1355-1363.	2.0	209
175	Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2186-2196.	1.2	91
176	Vascular Lipid Accumulation, Lipoprotein Oxidation, and Macrophage Lipid Uptake in Hypercholesterolemic Zebrafish. <i>Circulation Research</i> , 2009, 104, 952-960.	2.0	225
177	Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. <i>Blood</i> , 2009, 114, 5225-5235.	0.6	107
178	Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. <i>Journal of Clinical Investigation</i> , 2009, 119, 1335-1349.	3.9	397
179	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1653-1662.	1.2	104
180	Lipoprotein Management in Patients With Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1512-1524.	1.2	466

#	ARTICLE	IF	CITATIONS
181	Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume. <i>Journal of the American College of Cardiology</i> , 2008, 52, 24-32.	1.2	92
182	Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice. <i>Circulation</i> , 2008, 118, 743-753.	1.6	143
183	Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. <i>European Heart Journal</i> , 2008, 30, 107-115.	1.0	99
184	Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. <i>Circulation</i> , 2008, 117, 3206-3215.	1.6	170
185	Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia. <i>Circulation</i> , 2008, 118, 672-677.	1.6	90
186	A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. <i>Journal of Lipid Research</i> , 2008, 49, 2230-2239.	2.0	290
187	Cholesteryl Ester Hydroperoxides Are Biologically Active Components of Minimally Oxidized Low Density Lipoprotein. <i>Journal of Biological Chemistry</i> , 2008, 283, 10241-10251.	1.6	89
188	Natural Antibodies in Murine Atherosclerosis. <i>Current Drug Targets</i> , 2008, 9, 190-195.	1.0	41
189	The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. <i>Current Opinion in Lipidology</i> , 2008, 19, 369-377.	1.2	106
190	Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. <i>Journal of Clinical Investigation</i> , 2008, 118, 2917-2928.	3.9	146
191	A Diet-Induced Hypercholesterolemic Murine Model to Study Atherogenesis Without Obesity and Metabolic Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 878-885.	1.1	88
192	Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1788-1795.	1.1	220
193	Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 175-181.	1.1	78
194	Inhibition of the Renin-Angiotensin System Abolishes the Proatherogenic Effect of Uremia in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1080-1086.	1.1	28
195	Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. <i>Journal of Clinical Investigation</i> , 2007, 117, 153-164.	3.9	177
196	ApoE <sup>-/-</sup> /Fas <sup>-/-</sup> C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. <i>Journal of Lipid Research</i> , 2007, 48, 794-805.	2.0	62
197	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. <i>Journal of Lipid Research</i> , 2007, 48, 425-433.	2.0	215
198	Promise of Immune Modulation to Inhibit Atherogenesis—Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2007, 50, 547-550.	1.2	27

#	ARTICLE	IF	CITATIONS
199	Autoantibodies to oxidized LDL and cardiovascular risk: The Framingham Offspring Study. <i>Atherosclerosis</i> , 2006, 189, 364-368.	0.4	36
200	Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1803-1810.	1.2	82
201	Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2219-2228.	1.2	174
202	Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2436-2443.	1.2	64
203	A Natural Antibody to Oxidized Cardiolipin Binds to Oxidized Low-Density Lipoprotein, Apoptotic Cells, and Atherosclerotic Lesions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2096-2102.	1.1	63
204	Impaired Regulatory T-Cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule. <i>Circulation</i> , 2006, 114, 2047-2055.	1.6	201
205	Minimally Oxidized LDL Offsets the Apoptotic Effects of Extensively Oxidized LDL and Free Cholesterol in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1169-1176.	1.1	81
206	A new category in JLR: Patient-Oriented Research Articles. <i>Journal of Lipid Research</i> , 2006, 47, 1117.	2.0	0
207	A comprehensive classification system for lipids. <i>Journal of Lipid Research</i> , 2005, 46, 839-861.	2.0	1,348
208	A comprehensive classification system for lipids. <i>European Journal of Lipid Science and Technology</i> , 2005, 107, 337-364.	1.0	94
209	Adoptive transfer of <i>Porphyromonas gingivalis</i> heat shock protein epitope-specific T-cell lines into SCID mice in experimental atherosclerosis. <i>The Journal of the Korean Academy of Periodontology</i> , 2005, 35, 1.	0.1	0
210	High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. <i>Journal of Lipid Research</i> , 2005, 46, 769-778.	2.0	52
211	T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1596-1601.	3.3	299
212	Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits. <i>Circulation</i> , 2005, 111, 3302-3309.	1.6	52
213	Toll-Like Receptor 4-Dependent and -Independent Cytokine Secretion Induced by Minimally Oxidized Low-Density Lipoprotein in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1213-1219.	1.1	243
214	Phosphocholine as a pattern recognition ligand for CD36. <i>Journal of Lipid Research</i> , 2005, 46, 969-976.	2.0	103
215	Thematic review series: The Immune System and Atherogenesis. The role of natural antibodies in atherogenesis. <i>Journal of Lipid Research</i> , 2005, 46, 1353-1363.	2.0	224
216	Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2005, 353, 46-57.	13.9	636

#	ARTICLE	IF	CITATIONS
217	Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. <i>American Heart Journal</i> , 2005, 150, 1007-1014.	1.2	30
218	You are right too!. <i>Journal of Clinical Investigation</i> , 2005, 115, 2072-2075.	3.9	70
219	Plasma Triacylglycerol and HDL Cholesterol Concentrations Confirm Self-Reported Changes in Carbohydrate and Fat Intakes in Women in a Diet Intervention Trial. <i>Journal of Nutrition</i> , 2004, 134, 342-347.	1.3	36
220	Changes in Dietary Fat Intake Alter Plasma Levels of Oxidized Low-Density Lipoprotein and Lipoprotein(a). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 498-503.	1.1	97
221	Thematic Reviews on the Pathogenesis of Atherosclerosis. <i>Journal of Lipid Research</i> , 2004, 45, 991-992.	2.0	4
222	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. <i>Circulation</i> , 2004, 110, 1406-1412.	1.6	209
223	Critical Role of Macrophage 12/15-Lipoxygenase for Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Circulation</i> , 2004, 110, 2024-2031.	1.6	189
224	High-Density Lipoproteins Retard the Progression of Atherosclerosis and Favorably Remodel Lesions Without Suppressing Indices of Inflammation or Oxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1904-1909.	1.1	107
225	Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a). <i>Circulation</i> , 2004, 109, 3164-3170.	1.6	229
226	Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2307-2312.	1.1	80
227	Apoptotic Cells with Oxidation-specific Epitopes Are Immunogenic and Proinflammatory. <i>Journal of Experimental Medicine</i> , 2004, 200, 1359-1370.	4.2	310
228	Alterations in Plasma Vitamin E Distribution in Type 2 Diabetic Patients With Elevated Plasma Phospholipid Transfer Protein Activity. <i>Diabetes</i> , 2004, 53, 2633-2639.	0.3	34
229	Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. <i>Journal of Lipid Research</i> , 2004, 45, 1347-1354.	2.0	25
230	long-term effect of combined vitamins e and c on coronary and peripheral endothelial function. <i>Journal of the American College of Cardiology</i> , 2004, 43, 629-634.	1.2	84
231	Antioxidant Vitamin Supplements and Cardiovascular Disease. <i>Circulation</i> , 2004, 110, 637-641.	1.6	359
232	Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR $\alpha$ , $\beta$ , and $\delta$ . <i>Journal of Clinical Investigation</i> , 2004, 114, 1564-1576.	3.9	494
233	IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. <i>Journal of Clinical Investigation</i> , 2004, 114, 427-437.	3.9	335
234	IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. <i>Journal of Clinical Investigation</i> , 2004, 114, 427-437.	3.9	208

#	ARTICLE	IF	CITATIONS
235	Reply to "Humoral immunity and atherosclerosis". <i>Nature Medicine</i> , 2003, 9, 244-245.	15.2	4
236	Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between <i>Streptococcus pneumoniae</i> and oxidized LDL. <i>Nature Medicine</i> , 2003, 9, 736-743.	15.2	683
237	Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 360-370.	1.2	310
238	Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids?. <i>FEBS Letters</i> , 2003, 551, 104-106.	1.3	129
239	Journal of Lipid Research: The New Era in Lipid Science and Medicine. <i>Journal of Lipid Research</i> , 2003, 44, 1267.	2.0	4
240	Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a). <i>Journal of Biological Chemistry</i> , 2003, 278, 52841-52847.	1.6	116
241	Antioxidant Vitamins C and E Improve Endothelial Function in Children With Hyperlipidemia. <i>Circulation</i> , 2003, 108, 1059-1063.	1.6	214
242	The Autoreactivity of Anti-Phosphorylcholine Antibodies for Atherosclerosis-Associated Neo-Antigens and Apoptotic Cells. <i>Journal of Immunology</i> , 2003, 170, 6151-6157.	0.4	103
243	Minimally Modified LDL Binds to CD14, Induces Macrophage Spreading via TLR4/MD-2, and Inhibits Phagocytosis of Apoptotic Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 1561-1568.	1.6	338
244	Oxidized low density lipoprotein and innate immune receptors. <i>Current Opinion in Lipidology</i> , 2003, 14, 437-445.	1.2	164
245	Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. <i>Journal of Clinical Investigation</i> , 2003, 111, 897-906.	3.9	289
246	C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13043-13048.	3.3	459
247	Correlation of Antiphospholipid Antibody Recognition with the Structure of Synthetic Oxidized Phospholipids. <i>Journal of Biological Chemistry</i> , 2002, 277, 7010-7020.	1.6	177
248	Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E. <i>Journal of Biological Chemistry</i> , 2002, 277, 31850-31856.	1.6	106
249	Circulating Autoantibodies to Oxidized LDL Correlate With Impaired Coronary Endothelial Function After Cardiac Transplantation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 2044-2048.	1.1	51
250	Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte-Endothelial Interactions. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 101-107.	1.1	264
251	Epoxyisoprostane and Epoxycyclopentenone Phospholipids Regulate Monocyte Chemotactic Protein-1 and Interleukin-8 Synthesis. <i>Journal of Biological Chemistry</i> , 2002, 277, 7271-7281.	1.6	172
252	Influence of C3 Deficiency on Atherosclerosis. <i>Circulation</i> , 2002, 105, 3025-3031.	1.6	151

#	ARTICLE	IF	CITATIONS
253	Mechanical Aortic Injury in apoE-Deficient Mice as a Model for Development of Atherosclerosis: Demonstration of Leukocyte Rolling Early After Injury. <i>Ultrastructural Pathology</i> , 2002, 26, 251-260.	0.4	3
254	Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?. <i>Circulation</i> , 2002, 105, 2107-2111.	1.6	441
255	Lipid Lowering Reduces Oxidative Stress and Endothelial Cell Activation in Rabbit Atheroma. <i>Circulation</i> , 2002, 106, 1390-1396.	1.6	199
256	Innate and acquired immunity in atherogenesis. <i>Nature Medicine</i> , 2002, 8, 1218-1226.	15.2	604
257	Splenic immunity and atherosclerosis: a glimpse into a novel paradigm?. <i>Journal of Clinical Investigation</i> , 2002, 109, 721-724.	3.9	26
258	Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. <i>Journal of the American College of Cardiology</i> , 2001, 37, 766-774.	1.2	84
259	Atherosclerosis. <i>Cell</i> , 2001, 104, 503-516.	13.5	2,772
260	Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F <sub>2</sub> I <sub>2</sub> -VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. <i>Blood</i> , 2001, 97, 459-464.	0.6	34
261	The Oxidative Modification Hypothesis of Atherosclerosis Does It Hold for Humans?. <i>Trends in Cardiovascular Medicine</i> , 2001, 11, 93-102.	2.3	373
262	High-Fat, High-Cholesterol Diet Increases the Incidence of Gastritis in LDL Receptor <sup>-/-</sup> Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 991-996.	1.1	27
263	Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1333-1339.	1.1	197
264	Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor <sup>-/-</sup> Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 95-100.	1.1	147
265	Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Circulation</i> , 2001, 104, 1887-1893.	1.6	450
266	12/15-Lipoxygenase Translocation Enhances Site-specific Actin Polymerization in Macrophages Phagocytosing Apoptotic Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 19431-19439.	1.6	65
267	Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk. <i>Circulation</i> , 2001, 103, 1930-1932.	1.6	121
268	Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E <sup>-/-</sup> Mice. <i>Circulation</i> , 2001, 103, 2277-2282.	1.6	225
269	Anticardiolipin Antibodies From Patients With the Antiphospholipid Antibody Syndrome Recognize Epitopes in Both I <sup>2</sup> -Glycoprotein 1 and Oxidized Low-Density Lipoprotein. <i>Circulation</i> , 2001, 103, 941-946.	1.6	63
270	Maternal Hypercholesterolemia and Treatment During Pregnancy Influence the Long-Term Progression of Atherosclerosis in Offspring of Rabbits. <i>Circulation Research</i> , 2001, 89, 991-996.	2.0	139



#	ARTICLE	IF	CITATIONS
271	Scavenger Receptors, Oxidized LDL, and Atherosclerosis. <i>Annals of the New York Academy of Sciences</i> , 2001, 947, 214-223.	1.8	260
272	Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. <i>Journal of Lipid Research</i> , 2001, 42, 1474-1482.	2.0	134
273	The Binding of Oxidized Low Density Lipoprotein to Mouse CD36 Is Mediated in Part by Oxidized Phospholipids That Are Associated with Both the Lipid and Protein Moieties of the Lipoprotein. <i>Journal of Biological Chemistry</i> , 2000, 275, 9163-9169.	1.6	170
274	Immunological responses to oxidized LDL. <i>Free Radical Biology and Medicine</i> , 2000, 28, 1771-1779.	1.3	136
275	Short-Term Feeding of Atherogenic Diet to Mice Results in Reduction of HDL and Paraoxonase That May Be Mediated by an Immune Mechanism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1946-1952.	1.1	74
276	In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 689-697.	1.1	119
277	Maternal Hypercholesterolemia Enhances Atherogenesis in Normocholesterolemic Rabbits, Which Is Inhibited by Antioxidant or Lipid-Lowering Intervention During Pregnancy. <i>Circulation Research</i> , 2000, 87, 946-952.	2.0	128
278	Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis. <i>Journal of Biological Chemistry</i> , 2000, 275, 17527-17535.	1.6	371
279	Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. <i>Journal of Clinical Investigation</i> , 2000, 105, 1731-1740.	3.9	602
280	Autoantibodies to OxLDL Are Decreased in Individuals With Borderline Hypertension. <i>Hypertension</i> , 1999, 33, 53-59.	1.3	113
281	Intracranial Arteries of Human Fetuses Are More Resistant to Hypercholesterolemia-Induced Fatty Streak Formation Than Extracranial Arteries. <i>Circulation</i> , 1999, 99, 2003-2010.	1.6	139
282	All ApoB-Containing Lipoproteins Induce Monocyte Chemotaxis and Adhesion When Minimally Modified. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1437-1446.	1.1	59
283	Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. <i>Journal of Nuclear Cardiology</i> , 1999, 6, 41-53.	1.4	122
284	Interleukin-4-dependent production of PPAR- $\beta$ ligands in macrophages by 12/15-lipoxygenase. <i>Nature</i> , 1999, 400, 378-382.	13.7	822
285	Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. <i>Lancet</i> , The, 1999, 354, 1234-1241.	6.3	564
286	Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. <i>Journal of Clinical Investigation</i> , 1999, 103, 117-128.	3.9	494
287	Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. <i>Journal of Clinical Investigation</i> , 1999, 103, 1597-1604.	3.9	475
288	Basic Requirements for Investigational New Drug and New Drug Application Approval for an Antioxidant Compound in Cardiovascular Disease. <i>American Journal of Cardiology</i> , 1998, 81, 50F-51F.	0.7	1

#	ARTICLE	IF	CITATIONS
289	Immunization of LDL Receptor-Deficient Mice With Homologous Malondialdehyde-Modified and Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neopeptides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1972-1982.	1.1	296
290	An Animal Model to Study Local Oxidation of LDL and Its Biological Effects in the Arterial Wall. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 884-893.	1.1	79
291	To E or Not To E-How Do We Tell?. <i>Circulation</i> , 1998, 98, 2785-2787.	1.6	33
292	Abnormal Iron Deposition Associated With Lipid Peroxidation in Transgenic Mice Expressing Interleukin-6 in the Brain. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 268-282.	0.9	64
293	Oxidized phospholipids and isoprostanes in atherosclerosis. <i>Current Opinion in Lipidology</i> , 1998, 9, 441-448.	1.2	146
294	Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo. <i>Journal of Biological Chemistry</i> , 1997, 272, 13597-13607.	1.6	691
295	Angiotensin II Increases Macrophage-mediated Modification of Low Density Lipoprotein via a Lipoxygenase-dependent Pathway. <i>Journal of Biological Chemistry</i> , 1997, 272, 21609-21615.	1.6	112
296	Fibroblasts That Overexpress 15-Lipoxygenase Generate Bioactive and Minimally Modified LDL. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 3639-3645.	1.1	66
297	The Role of Oxidized LDL in Atherogenesis: Immunological Response and Anti-phospholipid Antibodies. <i>Annals of the New York Academy of Sciences</i> , 1997, 811, 88-99.	1.8	48
298	Oxidized Low Density Lipoproteins in Atherogenesis: Role of Dietary Modification. <i>Annual Review of Nutrition</i> , 1996, 16, 51-71.	4.3	137
299	Increased Autoantibody Titers Against Epitopes of Oxidized LDL in LDL Receptor-Deficient Mice With Increased Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1569-1576.	1.1	222
300	Effect of the Antioxidant <i>N,N</i> -Diphenyl 1,4-Phenylenediamine (DPPD) on Atherosclerosis in ApoE-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 1625-1630.	1.1	91
301	Aminoguanidine Has Both Pro-oxidant and Antioxidant Activity Toward LDL. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 367-376.	1.1	58
302	Enhanced Levels of Lipoperoxides in Low Density Lipoprotein Incubated with Murine Fibroblasts Expressing High Levels of Human 15-Lipoxygenase. <i>Journal of Biological Chemistry</i> , 1995, 270, 5191-5197.	1.6	100
303	Immunological Evidence for the Presence of Advanced Glycosylation End Products in Atherosclerotic Lesions of Euglycemic Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 571-582.	1.1	124
304	The Role of Oxidized LDL in the Atherogenic Process. <i>Journal of Atherosclerosis and Thrombosis</i> , 1994, 1, 71-75.	0.9	19
305	Susceptibility of low-density lipoprotein to oxidative modification. <i>American Journal of Medicine</i> , 1993, 94, 347-349.	0.6	51
306	Studies on the Ability of Dietary Supplementation with $\beta$ -Carotene to Protect Low-Density Lipoprotein from Oxidative Modification. <i>Annals of the New York Academy of Sciences</i> , 1993, 691, 200-206.	1.8	3

#	ARTICLE	IF	CITATIONS
307	Beyond Cholesterol. <i>New England Journal of Medicine</i> , 1989, 320, 915-924.	13.9	5,695
308	Detection of two apolipoprotein B species (apoBc and apoBg) by a monoclonal antibody. <i>Atherosclerosis</i> , 1987, 65, 247-256.	0.4	15
309	Intensive drug therapy of hypercholesterolemia. <i>American Heart Journal</i> , 1987, 113, 603-609.	1.2	19
310	Generation of region-specific antibodies to modified proteins. <i>Journal of Clinical Laboratory Analysis</i> , 1987, 1, 266-271.	0.9	1
311	Monoclonal antibody detects Ag polymorphism of apolipoprotein B. <i>FEBS Letters</i> , 1986, 202, 54-58.	1.3	33
312	[19] Immunochemical isolation and identification of glucosylated apolipoproteins. <i>Methods in Enzymology</i> , 1986, 128, 354-364.	0.4	2
313	A COMMUNITY STUDY OF HIGH DENSITY LIPOPROTEINS IN ADULT NONINSULIN-DEPENDENT DIABETICS. <i>American Journal of Epidemiology</i> , 1983, 117, 186-192.	1.6	95
314	Receptor-mediated Catabolism of Low Density Lipoprotein in Man. QUANTITATION USING GLUCOSYLATED LOW DENSITY LIPOPROTEIN. <i>Journal of Clinical Investigation</i> , 1983, 71, 950-959.	3.9	185
315	Familial Hypercholesterolemia. <i>Journal of Clinical Investigation</i> , 1982, 70, 823-831.	3.9	11
316	Analysis of lipids and endothelial and smooth muscle cells of umbilical cord in familial homozygous hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 1981, 30, 285-289.	1.5	7
317	Normalization of Triglycerides in Type IV Hyperlipoproteinemia Fails to Correct Low Levels of High-Density-Lipoprotein Cholesterol. <i>New England Journal of Medicine</i> , 1980, 303, 907-914.	13.9	64
318	Effects of Diet on Apoprotein E Levels and on the Apoprotein E Subspecies in Human Plasma Lipoproteins*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1980, 50, 521-528.	1.8	48
319	Effects of short-term high carbohydrate, fat-free diet on plasma levels of Apo C-II and Apo C-III and on the Apo C subspecies in human plasma lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 1980, 29, 654-661.	1.5	49
320	Successful plasmapheresis in a 4-year-old child with homozygous familial hypercholesterolemia. <i>Journal of Pediatrics</i> , 1980, 97, 615-618.	0.9	20
321	Structure, Immunology, and Cell Reactivity of Low Density Lipoprotein from Umbilical Vein of a Newborn Type II Homozygote. <i>Journal of Clinical Investigation</i> , 1980, 66, 123-129.	3.9	11
322	Type III hyperlipoproteinemia. <i>American Journal of Medicine</i> , 1979, 66, 303-310.	0.6	33
323	Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. <i>Metabolism: Clinical and Experimental</i> , 1979, 28, 1001-1010.	1.5	184
324	Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 1979, 28, 221-229.	1.5	73

#	ARTICLE	IF	CITATIONS
325	Effects of estrogen therapy on apolipoprotein E in type III hyperlipoproteinemia. <i>Metabolism: Clinical and Experimental</i> , 1979, 28, 1171-1177.	1.5	34
326	Elevated Cholesterol and Bile Acid Synthesis in a Young Patient with Homozygous Familial Hypercholesterolemia. <i>Journal of Clinical Investigation</i> , 1979, 64, 756-760.	3.9	28
327	Thyroid Hormone and Thyrotropin Levels in Patients Placed on Colestipol Hydrochloride*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1978, 46, 838-840.	1.8	30
328	Alterations in levels and interrelations of plasma apolipoproteins induced by diet. <i>Metabolism: Clinical and Experimental</i> , 1976, 25, 261-275.	1.5	165